Celcuity Q4 net loss $18.8M; FY net loss $63.8M; cash into H1 2026; VIKTORIA-1 topline data H2 2024

Celcuity Inc.

Net loss Q4 2023 $18.8M ($0.65 loss per share) vs $11.6M ($0.69) in Q4 2022.
Full year 2023 net loss $63.8M ($2.69 per share) vs $40.4M ($2.64) in 2022.
Raised $65M from equity sale; cash expected to fund operations into first half of 2026.
Phase 3 VIKTORIA-1 trial on track to report topline data for PIK3CA wild type subgroup H2 2024.
First patient dosed in Phase 1b/2 trial of gedatolisib + darolutamide for mCRPC in February 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Celcuity Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $18.8 million, or $0.65 loss per share, compared to a net loss of $11.6 mill, EPS $0.65 loss per share.

Period: the fourth quarter and fiscal year ended December 31, 2023
Net income: Net loss for the fourth quarter of 2023 was $18.8 million, or $0.65 loss per share, compared to a net loss of $11.6 mill
EPS: $0.65 loss per share
Result: reported results

Exact text from the filing

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2023

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Celcuity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011514

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.